A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.
Key facts
- Who runs it
- Xuanzhu Biopharmaceutical Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 500 people, planned
- Started
- 30 Jul 2025
- Planned end
- Aug 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Anaprazole + Rabeprazole placebo
- Rabeprazole + Anaprazole placebo
- Record updated
- 29 September 2025
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- The patients provided voluntary signed informed consent forms
- Aged ≥18 years and ≤75 years old
- Endoscopically diagnosed as reflux esophagitis (LA grade B-D) within 14 days before randomization
Who cannot take part
- Patients with concomitant diseases that may affect the esophagus or esophageal motility and, could potentially influence the efficacy evaluation
- Patients with a history of prior surgical procedures that could potentially impact esophageal function, or surgeries
- Patients with a history of mental illness or a history of drug or alcohol abuse within 12 months prior to screening
- Patients who had used proton pump inhibitors at therapeutic doses within 14 days prior to randomization
- Patients who had used therapeutic doses of other drugs for treating acid reflux within 7 days prior to randomization
- Patients required to continue receiving non-steroidal anti-inflammatory drugs (NSAIDs), systemic glucocorticoids, or clopidogrel during the trial period
- Patients whose assessment may be affected by alcohol, drug, or medication withdrawal during the study
- Pregnant or lactating women, as well as patients planning to conceive within 30 days before randomization and up to 6 months following the trial completion
- Patients who had participated in other drug clinical trials within 3 months prior to randomization
- Researchers believe that patients with uncontrolled primary diseases are not suitable for clinical trials, particularly those with a history of severe conditions affecting the cardiovascular, nervous, respiratory, hepatic, renal, or other systems
- Patients confirmed to have active peptic ulcers or active upper/lower gastrointestinal bleeding within the last 30 days via esophagogastroduodenoscopy (EGD)
- Patients with a history of Zollinger-Ellison syndrome, achalasia of the cardia, secondary esophageal motility disorders, irritable bowel syndrome, inflammatory bowel disease, or other gastrointestinal functional disorders
- Patients with a history of malignant tumor or having received treatment for malignant tumor within 5 years prior to randomization
- Patients who tested positive for HIV, HBsAg, and/or HCV antibodies during screening
- Patients with malignant tumors or a predisposition to malignancy in the stomach or esophagus
- Patients with poorly controlled diabetes or hypertension
- Patients with a known allergy to the components or ingredients of Anaprazole or Rabeprazole
- Patients with other conditions deemed by the researchers as unsuitable for participation in this clinical trial
- Patients with abnormal liver function: AST and/or ALT levels ≥2.0×ULN, and/or total bilirubin (TBIL) levels ≥1.5×ULN
- Patients with abnormal renal function: Serum creatinine levels ≥1.5×ULN, blood urea or blood urea nitrogen levels ≥1.5×ULN
- Patients with clinically significant ECG abnormalities, including QTc interval prolongation (QTcF ≥450 ms for men and QTcF ≥470 ms for women)
- Patients who were unable to undergo esophagogastroduodenoscopy (EGD)
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This Phase III clinical trial is designed to assess the efficacy and safety of Anaprazole 60 mg once daily (QD) administered over a period of up to 8 weeks, compared with Rabeprazole 20 mg QD, in patients with reflux esophagitis.
The 2 groups in the trial
- AnaprazoleTreatment being tested
Anaprazole 3 tablets (20 mg/tablet) + Rabeprazole placebo 1 tablet (0.16 g/tablet), administered orally 30-60 minutes before breakfast once daily for up to 8 weeks. After 4 weeks of continuous treatment, if endoscopic evaluation confirms the cure of reflux esophagitis, treatment may be discontinued.
Treatment: Anaprazole + Rabeprazole placebo
- RabeprazoleExisting treatment, for comparison
Rabeprazole 1 tablet (20 mg/tablet) + Anaprazole placebo 3 tablets (0.2 g/tablet), orally administered 30-60 minutes before breakfast once daily for up to 8 weeks. After 4 weeks of continuous treatment, if endoscopic evaluation confirms the cure of reflux esophagitis, treatment may be discontinued.
Treatment: Rabeprazole + Anaprazole placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Anaprazole in the Treatment of Reflux Esophagitis: A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Positive-Controlled Phase III Clinical Trial.
- Criteria questions
- Built from NCT07010107, who can take part
- Record updated
- 29 September 2025